To complement this analysis and define the response to MEK inhibition in an orthogonal NF1-mutant glioblastoma model, we performed scRNA-Seq of human GBM43 cells treated with vehicle DMSO, selumetinib, or a second MEK inhibitor, trametinib (Figure 3G). The gene discussed is MAP2K7; the disease is glioblastoma.